Personalized sirolimus regimen for vascular malformations: a retrospective analysis of VASE cohort
Abstract Background The mTOR inhibitor Sirolimus was shown to improve symptoms in patients with slow-flow vascular malformations, but long-term continuous use is limited by cumulative toxicity. A personalized approach with intermittent regimens may offer similar efficacy with fewer adverse effects (...
Gardado en:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BMC
2025-12-01
|
| Series: | Orphanet Journal of Rare Diseases |
| Assuntos: | |
| Acceso en liña: | https://doi.org/10.1186/s13023-025-04151-y |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|